Dawnzera (HAE)
Get notified when a new coverage update is posted for this brand.
Therapeutic Area
Rare Disease / Immunology — Hereditary Angioedema Prophylaxis
Primary Competitor
Takhzyro, Orladeyo, Haegarda
Current Watch Item
Step-therapy exposure vs. Takhzyro
Payers with Published Policy
3 backed by a citable published policy document
PA Criteria Defined
Exception Pathway Published
Time to First Policy
Brand Access Summary
Dawnzera is entering an HAE prophylaxis market with three established competitors. The central risk is not basic coverage but step-therapy exposure — several early policies require a documented trial and failure of Takhzyro before Dawnzera is authorized, with exception pathways still rare.
Indication-centered view
Policy Posture and UM Summary
| SEGMENT | POLICY POSTURE | COMMON UM CRITERIA | LAUNCH RISK |
|---|---|---|---|
| Commercial | 52% published / 41% PA defined | C1-INH level/functional assay confirmation; specialist-only prescribing (allergist/immunologist) | Step therapy against Takhzyro is the dominant early pattern |
| Medicare | 44% published / 33% PA defined | Confirmed HAE diagnosis plus attack-frequency documentation | Smaller Medicare-eligible HAE population slows policy volume |
| Medicaid | 38% published / 29% PA defined | State-by-state specialist-network access varies independently of drug policy | Access to an allergist/immunologist can gate the pathway before drug PA is reached |
Access build since launch
Launch Access Trend
Brand documents
Shared Documents
PDF, DOC, PNG or JPG · max 20 MB
Uploaded by Sophia Lee
Jun 8, 2026
Uploaded by Kevin Moore
May 27, 2026
Uploaded by Omar Hassan
May 18, 2026